Summit Therapeutics' Ivonescimab Shows PFS of 11.14 Months, Outperforms Merck's Keytruda in PD-L1 Positive Lung Cancer Trial

Sep 8, 2024, 03:30 PM

At the 2024 World Conference on Lung Cancer (WCLC) in San Diego, Summit Therapeutics presented groundbreaking data from their Phase 3 HARMONi-2 trial. The trial revealed that ivonescimab, an investigational therapy, significantly outperformed Merck's Keytruda in treating patients with PD-L1 positive advanced non-small cell lung cancer (NSCLC). Ivonescimab demonstrated a median progression-free survival (PFS) of 11.14 months compared to 5.82 months for Keytruda, reducing the risk of disease progression or death by 49% (HR=0.51, p<0.0001). The objective response rate (ORR) was 50% for ivonescimab versus 38.5% for Keytruda. This data marks a historic achievement in the field of lung cancer treatment, potentially setting a new standard of care.